HSAL3 represents a novel SE-driven oncogenic lncRNA, and siHSAL3-loaded nanoparticles emerge as promising therapeutic candidates for HCC treatment. The gene discussed is HEXIM2-AS2; the disease is hepatocellular carcinoma.